Jul 13,2021

Glytec Appoints Dr. Jordan Messler as Chief Medical Officer

Glytec, the only provider of cloud-based insulin management software across the continuum of care, today announced the appointment of Jordan Messler, MD, SFHM, FACP to Chief Medical Officer. In this new role, Dr. Messler will be responsible for spearheading continuous improvement initiatives for Glytec’s clinical strategy and product development while supporting the delivery, customer, quality and regulatory teams to ensure ethical and safe glycemic management best practices.

View Analyst & Ambassador Comments
Go to original news
Jul 14,2021

Teladoc Health and Microsoft Collaborate to Create a Unified Practice Experience for Clinicians

Teladoc Health today announced a collaboration with Microsoft in which Teladoc Health’s Solo platform for hospitals and health systems will be integrated into the Microsoft Teams environment to strengthen physician and patient access to best-in-class virtual healthcare. Clinicians already have the ability to securely access clinical data included within their electronic health record system via Teladoc Health Solo, and will be able to do so without having to leave the Teams environment.

COLLABORATION PARTNERSHIP

#product & service

#telehealth

#virtual care

View Analyst & Ambassador Comments
Go to original news
Jul 15,2021

Glytec appoints Chief Medical Officer

Cloud-based insulin management software developer Glytec announced today that it appointed Dr. Jordan Messler as chief medical officer. Messler’s responsibilities as the company’s CMO include spearheading continuous improvement initiatives for Glytec’s clinical strategy and product development.

View Analyst & Ambassador Comments
Go to original news
Jul 19,2021

Sweetch Secures $20 Million Series A to Accelerate Fully Automated Hyper-Personalized Engagement Between Health Ecosystem Players and People With Chronic Conditions

Sweetch, a digital therapeutics innovator and creator of the hyper-personalized engagement platform for chronic conditions, announced the completion of a $20 million Series A round of funding. The funds will be directed toward the company’s continued global expansion and further development of its artificial intelligence (AI) and emotional intelligence (EI) behavioral science technology that engages individuals to achieve their health goals with the right message in the right tone, time and real-world context.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Jul 20,2021

ASCENSIA DIABETES CARE LAUNCHES PATIENT ASSISTANCE PROGRAM TO PROVIDE BROADER ACCESS TO EVERSENSE CONTINUOUS GLUCOSE MONITORING SYSTEM

Under the Program, which is available immediately, eligible patients starting or continuing with the Eversense CGM System will need to pay the first $100 of their out-of-pocket costs. Ascensia will then cover up to $300 of the remaining balance for each 90-day sensor. Any additional costs will be the system user’s responsibility. Overall, the Program has the potential to save eligible Eversense users up to $1,200 per year on their cumulative 90-day sensor out-of-pocket costs.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 20,2021

Brighter appoints Erik Lissner as interim CEO

Brighter AB (Publ) announced today that its Board of Directors appoints Erik Lissner as interim CEO of Brighter effective immediately. Current interim CEO, Christer Trägårdh, will take the position as Chairman of the Board. The company has signed a six-month contract with Lissner and both parties are open to discuss a permanent solution after this period.

View Analyst & Ambassador Comments
Go to original news
Jul 20,2021

A New Analysis Tool for Continuous Glucose Monitor Data

With the development of continuous glucose monitoring systems (CGMS), detailed glycemic data are now available for analysis. Yet analysis of this data-rich information can be formidable. The power of CGMS-derived data lies in its characterization of glycemic variability. In contrast, many standard glycemic measures like hemoglobin A1c (HbA1c) and self-monitored blood glucose inadequately describe glycemic variability and run the risk of bias toward overreporting hyperglycemia. Methods that adjust for this bias are often overlooked in clinical research due to difficulty of computation and lack of accessible analysis tools.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 22,2021

Simulation Platform Development for Diabetes and Technology Self-Management

Specialized education is critical for optimal insulin pump use but is not widely utilized or accessible. We aimed to (1) test the usability and acceptability of A1Control, a simulation platform supporting insulin pump education, and (2) determine predictors of performance.

CLINICAL STUDY

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jul 22,2021

Efficacy of a Smart Insulin Pen Cap for the Management of Patients with Uncontrolled Type 2 Diabetes: A Randomized Cross-Over Trial

We studied a smart insulin pen cap that can be plugged to several brand of insulin pens, to track insulin administration via smart-phone Bluetooth technology, with alarm/reminder system aiming.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 22,2021

ABBOTT REPORTS SECOND-QUARTER 2021 RESULTS

i) Sales growth of 39.5 percent; organic sales growth of 35.0 percent ii)GAAP diluted EPS from continuing operations growth of 120.0 percent; adjusted diluted EPS growth of 105.3 percent iii)Second-quarter sales, excluding COVID-19 testing-related sales, grew 12.3 percent on a reported basis and 11.3 percent on an organic basis compared to sales in 2019 iv)Achieved strong sales growth across all four major business areas v) Full-year forecast continues to reflect strong, double-digit EPS growth on both a GAAP and adjusted basis

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES